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Abstract
Background: Little is known about risk factors for chronic and mucoid Pseudomonas aeruginosa (Pa) infection in
cystic fibrosis (CF) adults, and whether the prevalence is changing.
Methods: We employed a retrospective cohort to analyze data from a single adult CF center (2002 to 2012).
Regression models were used to assess independent predictors and change in prevalence of chronic and mucoid
Pa infection over time.
Results: The odds ratio of mucoid Pa infection was significantly less in individuals with better baseline lung
function (OR 0.84,95%CI:0.77–0.92) and those diagnosed after the age of 25 (OR 0.21, 95%CI:0.05–0.95). The
prevalence of chronic Pa and mucoid Pa decreased during the time interval. After adjusting for confounders, the
observed decrease in chronic and mucoid Pa between 2002 and 2012 was no longer significant.
Conclusions: The prevalence of chronic and mucoid Pa is decreasing. Larger studies are needed to confirm these
regional trends and their significance.
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Background
Cystic Fibrosis (CF) is the most common severe monogenic
disorder among Caucasians [1]. CF was once considered a
fatal childhood disease, but with advances in care, survival
has steadily improved. Mortality decreased by 1.8% per year
between the years 2000 to 2012, and if this observed rate
continues, individuals born with CF in 2010 are predicted
to have a median life expectancy of more than 50 years [2].
In 2013, half of the US CF population was 18 years of age
or older [3]. Chronic lung disease in CF, however, continues
to cause significant morbidity, and respiratory failure is the
leading cause of death in this population [4]. Chronic endo-
bronchial infections are central in the pathogenesis of
chronic lung disease [5].
Pseudomonas aeruginosa (Pa) is the most common cul-
tured respiratory pathogen in CF, and in children, Pa is as-
sociated with a more rapid decline in lung function and
worse survival [6–8]. Prior reports estimated that by age
eighteen, 80% of individuals with CF are infected with Pa
[9]. Over time, most individuals with CF become chronic-
ally infected with Pa, and a mucoid phenotype of Pa fre-
quently becomes the predominant form found in culture
[10, 11]. Chronic and mucoid Pa infections are associated
with increased morbidity and mortality when compared to
individuals not infected with Pa [12, 13]. Additionally, due
to formation of biofilms, development of antibiotic resist-
ance and overall bacterial abundance, this form of Pa
infection is challenging to eradicate [5, 14, 15].
Because of the challenges with eradicating chronic and
mucoid Pa, the focus of treatment has been on prevent-
ing the chronic infection [16]. Recent studies in children
demonstrated eradication of newly acquired Pa from air-
way is associated with delayed reacquisition of Pa even
after stopping antibiotics [17–20]. These studies suggest
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that development of chronic Pa infection might be de-
creasing, but this has never been formally investigated in
the adult CF population. Using the CF Foundation Pa-
tient Registry a recent study showed a decline in both
the incidence and prevalence of Pa between 2006 and
2012 [21]. This study, however, did not look specifically
at chronic or mucoid Pa infection.
We hypothesize the prevalence of chronic and mucoid
Pa lung infection in the older CF population is decreasing
with time and there are independent predictors of chronic
and mucoid Pa infection in CF adults, which may be
unique compared to the younger CF population. Using a
longitudinal adult CF cohort, we sought to assess the
change in both chronic and mucoid Pa infections between
2002 and 2012 and identify independent predictors of the
chronically infected and mucoid Pa states.
Methods
Population
A retrospective cohort study design was employed using
individuals age 18 or older receiving care through the
Adult CF Clinic at the University of Washington Medical
Center between 2002 and 2012. Patients were able to con-
tribute data from multiple years; however, all individuals
with no evaluable culture data during a 1-year period were
excluded for the calendar year in which the data was
absent. No imputation of missing data was performed.
Sensitivity analyses were performed to assess the impact
of missing data.
Definitions of predictors of interest
Both time independent and time dependent variables
were considered as potential independent predictors of
chronic and mucoid Pa. Time independent variables in-
cluded age at diagnosis, gender, CF mutation status, CF
transmembrane conductance regulator (CFTR) function
and baseline lung function. Time dependent covariates
included age, CF-related diabetes (CFRD) and pancreatic
insufficiency (PI). Age at diagnosis was examined both
as a continuous and binary variable. As a binary variable,
age at diagnosis was categorized as 25 years of age or
younger and greater than 25 years of age. CFTR function
was classified as minimal (class I, II, and III), and residual
(class IV and V). All remaining genotypes were grouped
together along with those with unknown mutations. The
residual CFTR function group was used as the comparator
group. CFRD was defined by receiving insulin, and PI was
defined as receiving pancreatic enzymes. Percent pre-
dicted forced expiratory volume in one second (FEV1) at
time of cohort entry was used to define baseline lung
function. When analyzing the change in prevalence of
both chronic Pa and mucoid Pa, potential confounding
variables included age, age of diagnosis, gender, CFTR
function, and baseline lung function. The inclusion of
confounding variables was made a priori.
Anticipating relatively small numbers of individuals
within each year, calendar time was divided into four
time periods (2002–2004, 2005–2007, 2008–2010, and
2011–2012) for analysis of change in prevalence. This
decision was made prior to analysis of the data. This div-
ision of the observation period balanced the number of
subjects within each time period.
Outcome definitions
The primary outcomes of interest for identification of risk
factors and change in prevalence were chronic Pa and mu-
coid Pa infection. Due to the frequency of respiratory cul-
turing in this cohort, chronic Pa infection was defined
using a modified definition of chronic Pa initially pro-
posed by Lee et al. [22]. Individuals were defined as
chronic when three or more respiratory cultures were pro-
vided in a calendar year and 50% or more were positive
for Pa. If only two cultures were obtained in a calendar
year, both cultures needed to be positive for Pa to be con-
sidered chronically infected. Those individuals who pro-
vided less than 2 cultures within a calendar year were
excluded from the primary analysis. A sensitivity analysis
was performed including all subjects regardless of the
number of cultures provided within a year. Mucoid Pa
was defined having at least one respiratory culture with
the mucoid phenotype during a calendar year. Sensitivity
analyses looking at the influence of CFTR function, dur-
ation of time periods, changes in cohort characteristics
and inhaled antibiotic use were also performed.
Analysis
Descriptive statistics were used to describe the cohort.
Continuous variables were reported as medians with inter
quartile ranges and categorical variables were reported as
proportions. To account for repeated measurements,
population averaged generalized estimating equation
(GEE) regression models with independent working cor-
relation were used to assess independent predictors and
change in prevalence of both chronic and mucoid Pa in-
fection over time [23]. When assessing independent pre-
dictors of chronic and mucoid Pa infection, a univariate
regression model was first used to screen for significant
variables. Those variables with a significance level less
than or equal to 0.1 were then included in a multivariable
regression model that included an indicator for time
period to account for changes in cohort over the observa-
tion period. Both univariate and multivariable regression
analysis were used when assessing the change in preva-
lence of chronic and mucoid Pa over time. Odds ratio with
a 95% confidence interval was used to report results of the
GEE models. Unless otherwise noted, a two-tailed P-value,
not adjusted for multiple comparisons, less than 0.05 was
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considered statistically significant. All analyses were per-
formed using STATA version 13 (StataCorp LP, College
Station, Texas). The University of Washington Institu-
tional Review Board approved this study (45798).
Results
Overview of cohort
During the observation period, data was collected from
402 individuals. The average observation period was
4.6 years (range 1–11 years). Demographic data for the
cohort from the year of entry is summarized in Table 1.
This cohort was dynamic with individuals aging or mi-
grating into the population throughout the observation
period. Additionally, some individuals left the cohort
due to death or out-migration. Changes in population
characteristics during the observation period are summa-
rized in Additional file 1: Table E1. The cohort increased
from 123 patients in 2002 to 211 patients in 2012.
Genotype data was available on 382 individuals (95%) in
the cohort. Over the 11 years, the proportion of individuals
homozygous for f508del decreased from 57.7 to 48.8%.
Mean population percent-predicted FEV1 increased from
59.0 to 68.0% of predicted. The proportion using an inhaled
anti-pseudomonal antibiotic remained relatively constant
during the observation period. A cross sectional compari-
son of cohort demographics between 2002 and 2012 based
on state of Pa infection and number of cultures is presented
in Additional file 1: Table E2 and E3 respectively.
Risk factors for chronic and mucoid Pa
Results of the univariate and multivariable analysis for
independent predictors of chronic Pa infection using a
modified Leeds definition and mucoid Pa are in Table 2.
Subjects with worse baseline lung function were signifi-
cantly more likely to have mucoid Pa (P-value < 0.001).
When comparing two groups with a 10% difference in
baseline lung function, the odds of having a mucoid Pa
infection was 16% less in the group with better lung
function (OR: 0.84, 95% CI: 0.77–0.92). Those individ-
uals diagnosed after the age of 25 were less likely to have
a mucoid Pa infection (OR: 0.21, 95% CI: 0.05–0.95). All
Table 1 Characteristics of cohort at time of entry into the
cohort
(N = 402)
Mean age, years (SD) 29.7 (9.4)
Median age of diagnosis, years (IQR) 1.5 (8)
Gender, % Female (N) 48.8 (196)
Race, % Caucasian (N) 94.3 (379)
Ethnicity, % Hispanic (N) 1.9 (7)
f508del status
Homozygous, % (N) 52.4 (200)
Heterozygous, % (N) 39.0 (149)
Other, % (N) 8.6 (33)
CFTR Mutation Classification ad
Minimal, % (N) 71.7 (274)
Residual, % (N) 10.7 (41)
Unclassified, % (N) 17.5 (67)
FEV1, % predicted (SD)
d 63.5 (26.0)
Co-morbidities
CF-related diabetes bd, % (N) 28.0 (109)
Pancreatic insufficiency cd, % (N) 86.3 (308)
Inhaled Antibiotic Used 49.5 (147)
Microbiology
Any form of Pseudomonas isolated, % (N) 64.2 (238)
Mucoid Pseudomonas phenotype, % (N) 48.0 (178)
SD standard deviation, IQR inter quartile range
aMinimal: Both alleles containing mutations resulting in minimal CFTR function
(Class 1, 2, or 3); Residual: at least one allele containing mutation resulting in
partial CFTR function (Class 4 or 5); Unclassified: at least one allele with
unknown CFTR function and if other allele function known, mutation resulting
in minimal CFTR function
bCF-related diabetes: use of insulin
cPancreatic insufficiency: use of pancreatic enzymes
dMissing data (N, %): CFTR Mutation Classification (20, 5.0%), FEV1 (47, 11.7%),
CFRD (12, 3.0%), PI (45, 11.2%), Inhaled antibiotic use (105, 26%)
Table 2 Independent predictors of chronic and mucoid Pa
infection
Chronic Pa Mucoid Pa
OR (95%CI) OR (95%CI)
Univariate
Age (yr) 0.83 (0.63–1.10) 0.82 (0.66–1.02)
Diagnosis
Age (yr) 0.96 (0.94–0.98) 0.97 (0.96–0.99)
Diagnosis after 25 years of age 0.12 (0.04–0.31) 0.21 (0.09–0.46)
Gender, female 1.07 (0.65–1.77) 0.94 (0.61–1.44)
CFTR functiona 1.94 (1.10–3.44) 2.61 (1.28–5.63)
CF-related diabetesb 1.02 (0.63–1.65) 0.88 (0.57–1.34)
Pancreatic insufficiencyc 2.21 (1.11–4.37) 2.52 (1.46–4.38)
Lung Functiond 0.90 (0.82–1.00) 0.79 (0.71–0.88)
Multivariablee
Age (yr) 1.03 (0.99–1.08) 1.00 (0.97–1.03)
Diagnosis
Age (yr) 0.96 (0.91–1.02) 1.01 (0.97–1.05)
Diagnosis after 25 years of age 0.18 (0.03–1.20) 0.21 (0.05-0.95)
CFTR functiona 0.51 (0.17–1.55) 0.99 (0.42-2.34)
Pancreatic insufficiencyc 1.23 (0.53–2.82) 1.58 (0.89–2.80)
Lung Functiond 0.91 (0.82–1.01) 0.84 (0.77–0.92)
aComparator group: Residual CFTR function: at least one allele containing
mutation resulting in partial CFTR function (Class 4 or 5)
bCF-related diabetes: use of insulin
cPancreatic insufficiency: use of pancreatic enzymes
d10% difference in percent predicted FEV1
eVariables with significance level ≤ 0.1 included in multivariable analysis
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other variables included in both the mucoid Pa and
chronic Pa multivariable models did not reach a signifi-
cance level less than 0.05 (Table 2).
Prevalence of chronic Pa over time
The prevalence of chronic Pa in those who provided at
least two respiratory cultures in a calendar year decreased
from 73.5% in 2002 to 67.0% in 2012 (Additional file 1:
Table E1). The average prevalence of chronic Pa infection
decreased by 5.9% from the 2002 to 2004 time period to
the 2011 to 2012 time period (Fig. 1). After adjusting for
gender, age, age at diagnosis, CFTR function and baseline
lung function, the odds ratio of chronic Pa infection in the
2011–2012 time period relative to 2002–2004 time period
was 0.82 (95% CI: 0.31–2.14) (Table 3). Relative to the
2002–2004 time period, odds ratio of chronic Pa infection
was not significantly different than other time periods. In
both the unadjusted and adjusted models of chronic
Pseudomonas infection, the P-values of the trend test for
time period were not significant (Test of trend: unadjusted
P = 0.25; adjusted P = 0.84) (Table 3).
Prevalence of mucoid Pa over time
The prevalence of isolating the mucoid phenotype of Pa on
respiratory culture in 2002 was 68.2% and in 2012 the
prevalence was 58.1% (Additional file 1: Table E1). The
mean prevalence of mucoid Pa decreased by 10.3% when
comparing the 2002–2004 time period and the 2011–2012
time period (Fig. 1). When comparing the 2011–2012 time
period to the 2002–2004 time period, the odds ratio of iso-
lating the mucoid Pa phenotype in culture was 0.64 (95%
CI: 0.43–0.96) with a significant test of trend (p = 0.04), but
after adjusting for potential confounding the change was no
longer significant (OR 0.55; 95% CI: 0.27–1.11) (Table 4).
Demographic data was similar between the chronic Pa by
modified Leeds definition and the mucoid Pa phenotype
group in 2002 and 2012 (Additional file 1: Table E4).
Sensitivity analysis
When restricting the cohort to only individuals homozy-
gous for the f508del mutation, a trend toward decreasing
prevalence of both chronic and mucoid Pa was observed
(Additional file 1: Table E5). This trend was not signifi-
cant for either group. Inclusion of all individuals who
provided less two respiratory cultures within a year as
free of chronic infection resulted in a significant de-
crease in the prevalence of chronic Pa infection (Test of
trend P-value 0.002) (Additional file 1: Table E6). Adjust-
ing for inhaled antibiotic use did not significantly change
the observed trend in prevalence of chronic or mucoid
Pa infection (Additional file 1: Table E7). Using a two
time period model (2002–2007, 2008–2012), the odds of
infection was decreased but not significantly in the later
time period relative to the early period for both chronic
Fig. 1 By time period, prevalence of chronic Pa by modified Leeds Criteria and mucoid Pa
Table 3 Odds ratio for prevalence of chronic Pseudomonas
aeruginosa infection using modified Leeds criteria
Adjusted
Year ORa (95% CI) ORb,c (95% CI)
2002–2004 - -
2005–2007 1.00 (0.65–1.53) 1.22 (0.42–3.52)
2008–2010 0.97 (0.60–1.56) 1.29 (0.55–3.00)
2011–2012 0.75 (0.46–1.21) 0.82 (0.31–2.14)
aTrend test p: 0.25
bTrend test p: 0.85
cAdjusted for age, gender, age at diagnosis, CFTR function (minimal: class 1, 2,
3; residual: class 4, 5; Unclassified), baseline lung function (percent
predicted FEV1)
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(OR 0.86; 95% CI: 0.62–1.21) and mucoid (0.78; 95% CI:
0.59–1.02) Pa infections.
Discussion
Respiratory failure is the leading cause of death in CF,
and Pa infection, particularly chronic and the mucoid
phenotype, has been associated with increased morbidity
and mortality [7, 10, 12, 13]. Using a single center adult
CF cohort, we observed a decrease in prevalence of both
chronic and mucoid Pa over an 11-year observation
period. In a multivariable model adjusting for potential
confounding and repeated usage of patients, the change
in prevalence of both chronic and mucoid Pa, however,
did not meet the pre-specified significance level of 0.05.
We found age of diagnosis, CFTR function, PI and lung
function to be predictors of both chronic and mucoid Pa
when using a univariate analysis. Age of diagnosis and
baseline lung function remained significant independent
predictors of mucoid Pa infection after adjusting our
analysis for potential confounding. This suggests that in
the adult CF population individuals are less likely to
have a mucoid Pa infection when they are either diag-
nosed at a later age or have preserved lung function.
While our observed change in Pa over time may be
due to chance, a possible explanation for the decreasing
prevalence over time is a change in the population char-
acteristics of this cohort. The hypothesis is supported
when looking at the change in mucoid Pa prevalence
during the observation period. A significant change in
prevalence over time was observed in the unadjusted
analysis of mucoid Pa. This association was no longer
significant after adjusting for clinical and demographic
variables that may confound the association between
time and change in prevalence. Comparing all individ-
uals making up the cohort in 2002 to 2012, the propor-
tion of individuals in the cohort homozygous for f508del
decreased. Along with this change there was an increase
in the proportion of individuals with an unknown CFTR
functional class. With genetic testing, the proportion of
adults diagnosed with CF has increased, and of these
newly diagnosed adults, fewer are homozygous for
f508del [24]. Residual CFTR function may result in less
chronic infection. A recent study demonstrated a de-
crease in the prevalence of Pa in respiratory cultures in a
group of individuals with the G551D mutation receiving
ivacaftor. CFTR having a role in innate host response to
infection was a postulated explanation [25]. While CFTR
function was not associated with chronic or mucoid Pa
infections in our single center cohort, the degree of
CFTR function may play an important role in develop-
ment of chronic and mucoid Pa infections and warrants
further exploration. Lastly, individuals with worse lung
function were more likely to have chronic forms of Pa
infection. The observed improvement in lung function
during the observation period may also explain the trend
in prevalence of both mucoid and chronic Pa.
Restricting the cohort to individuals homozygous for
the f508del mutation resulted in a trend, albeit non-
significant, toward lower prevalence of both chronic and
mucoid Pa. This trend suggests influences aside from
change in cohort demographics might be contributing to
the change in chronic Pa prevalence. One such influence
is the implementation of inhaled anti-pseudomonal anti-
biotics. Multiple prospective studies involving the use of
inhaled and oral anti-pseudomonal antibiotics have dem-
onstrated clearance of newly acquired Pa from respira-
tory culture [17, 18, 26]. Eradication of this form of Pa
from the airways has been associated with improved
lung function, fewer pulmonary exacerbations and im-
proved survival [19, 27]. Eradicating newly acquired Pa
with inhaled antibiotics is now the standard of care [28].
In the pediatric population, the practice of inhaled anti-
pseudomonal antibiotics to eradicate new acquisition of
Pa has been associated with a decline in prevalence of
chronic Pa infection [29–31]. Whether the attempts to
eradicate newly acquired Pa from the airways has trans-
lated into a reduction in the frequency of mucoid and
chronic Pa in adults with CF is unknown. Our study is
the first to analyze change in prevalence of mucoid and
chronic Pa in CF adults.
Knowledge about the factors associated with chronic Pa
can improve care in CF adults. Identifying risk factors for
development of chronic Pa can tailor care and ultimately
improve quality of life. In a prospective cohort study,
CFTR genotype, female gender, age of diagnosis, and pan-
creatic enzyme use were identified as risk factors for initial
Pa acquisition in children [32]. Predictors of chronic Pa,
however, have not been well described in the literature.
The limited literature may in part be due to no universally
agreed upon definition for chronic Pa. A variable amount
of time may lapse between first acquisition of Pa and
chronic Pa status, and aggressive attempts to eradicate
newly acquired Pa from the airways have lengthened the
Table 4 Odds ratio for prevalence of mucoid Pseudomonas
aeruginosa phenotype in culture
Adjusted
Year ORa(95% CI) ORb,c (95% CI)
2002–2004 - -
2005–2007 0.77 (0.56–1.06) 0.81 (0.40–1.67)
2008–2010 0.70 (0.57–1.03) 0.77 (0.39–1.52)
2011–2012 0.64 (0.43–0.96) 0.55 (0.27–1.11)
aTrend test p: 0.04
bTrend test p: 0.11
cAdjusted for age, gender, age at diagnosis, CFTR function (minimal: class 1, 2,
3; residual: class 4, 5; Unclassified), baseline lung function (percent
predicted FEV1)
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time between new acquisition and chronic Pa [30]. This
may limit our ability to extrapolate risk factors from newly
acquired Pa to chronic Pa. The mucoid phenotype of Pa
has been associated with increased morbidity and mortal-
ity in CF [12, 13] and has been associated with onset of
chronic Pa [33]. In children, gender, lower baseline lung
function, genotype and absence of MRSA in sputum
culture are risk factors associated with acquisition of the
mucoid Pa in respiratory culture [34]. Our study is the
first to describe independent predictors of chronic and
mucoid Pa infection in the adult CF population in the
post-pediatric inhaled tobramycin era. Of the predictors,
baseline lung function and being diagnosed with CF as an
adult appear to be the predominant predictors not being
infected with mucoid or chronic Pa. Being diagnosed with
CF as an adult is likely reflective of having a milder pheno-
type, which may correlate with degree of functional CFTR
[24]. Whether the predictors found in our study translate
to risk factors for the development of chronic and mucoid
Pa still needs to be determined.
There are several limitations to consider with this
study. Patients cared for at a single CF center were used
to conduct this analysis. This both limits generalizability
and the ability to detect smaller but clinically meaningful
changes in prevalence. Due to challenges eradicating
chronic Pa from the airways, a longer observation period
may be needed to detect a significant change in the
prevalence. To increase the number of observations
within each time period, a sensitivity analysis was per-
formed using only two time periods (2002–2007 and
2008–2012). This analysis showed a similar trend toward
decreasing prevalence but statistical significance was not
met. Incidence of developing chronic Pa may be a better
measurement of change, as it would not be influenced
by the challenges of eradicating chronic Pa. Our defin-
ition of chronic Pa used a modified form of the Leeds
criteria and relied on the number of cultures obtained
within a calendar year. Under the Leeds definition,
chronic Pa was defined as having respiratory cultures
positive for Pa in more than 50% of the months within a
12 month period. Collecting respiratory cultures at least
every 3 months was recommended when applying this
definition [22]. In our adult cohort, the frequency of re-
spiratory cultures on average was less than quarterly.
Application of the Leeds definition could have resulted
in significant misclassification due too few cultures
collected during the year. To reduce misclassification,
the analysis restricted the cohort to only include individ-
uals with two or more cultures in a calendar year. This
restriction reduced the number of observations available
for analysis, which further limited the study’s ability to
detect a significant change in prevalence. In our sensitiv-
ity analysis using all subjects irrespective of annual cul-
ture numbers, a significant decrease in the prevalence of
chronic Pa was observed even after adjusting for other
variables. This observation suggests that in a larger co-
hort the trend observed may be significant.
Conclusion
This analysis is one of the first in recent times to identify
independent predictors of mucoid and chronic Pa infec-
tion in CF adults and analyze how the prevalence of
both mucoid and chronic Pa infection in CF adults have
changed with time. What appears to be a decrease in the
frequency of chronic and mucoid Pa in recent years war-
rants further study at a national level to confirm these
regional trends and their significance.
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